MAPK1 and cancer: In other words, ERK-dependent tumor cells, including cancers driven by mutant RTK, RAS, BRAF, or MEK proteins, will have a vulnerability to hyperactivated ERK and that vulnerability can potentially be exploited by inhibition of feedback regulators like DUSP6.